Evaluation of Drug-Drug Interactions Using Drug-PIN® in Patients Receiving Avelumab Maintenance for Advanced Urothelial Carcinoma: Evidence from the MALVA Study (Meet-URO 25).

Authors

Giandomenico Roviello, Mattia Alberto Di Civita, Daniele Santini, Elisabetta Gambale, Lidia Strigari, Simone Scagnoli, Laura Pappalardo, Andrea Torchia, Andrea Botticelli, Serena Pillozzi, Lorenzo Antonuzzo

Published in

Oncology and therapy. Jun 13, 2026. Epub Jun 13, 2026.

Abstract

Polypharmacy is common in patients with advanced urothelial carcinoma (UC) receiving avelumab maintenance therapy, raising concerns about potential drug-drug interactions (DDIs).
We retrospectively analyzed patients enrolled in the multicenter MALVA study treated with avelumab maintenance. Concomitant medications were assessed using the Drug Interaction and Pharmacogenomics Information Network (Drug-PIN®). Drug-PIN® scores were calculated with and without avelumab and correlated with overall survival (OS) and progression-free survival (PFS).
Among 115 patients, Drug-PIN® scores showed wide inter-patient variability but were not significantly influenced by inclusion of avelumab. No significant differences in OS or PFS were observed across Drug-PIN® risk categories.
In this real-world cohort, polypharmacy and Drug-PIN® score did not impact survival outcomes, suggesting that, within the limitations of this exploratory analysis, Drug-PIN®-assessed DDI burden was not associated with survival outcomes in patients receiving avelumab maintenance therapy.

PMID:
42295550
Bibliographic data and abstract were imported from PubMed on 15 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.